FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2025”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of January 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 4,388m
- Biotech/Pharma received 53% of the total investment volume (EUR 2,321m) with immunology being the leading indication (27%)
- In January Truveta secured the highest transaction volume with EUR 307m, followed by Kardigan with EUR 288m and Innovaccer with EUR 264m
- Accelmed (United States) is the most active investor (by deal volume in 2025), followed by Y Combinator (United States) and F-Prime Capital (United States)
To access the full report, please click here.